Trial Profile
Use of Recombinant FVIIa to Mitigate Warfarin Anticoagulation Therapy-Mediated Bleeding in a Single Centre, Randomized, Placebo-controlled, Double-blind Clinical Trial
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Nov 2016
Price :
$35
*
At a glance
- Drugs Eptacog alfa (Primary) ; Warfarin
- Indications Haemophilia; Thrombasthenia
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 13 Apr 2015 New trial record